Literature DB >> 26574567

Factors Influencing Physician Counseling on Cardiovascular Risk.

Val Rakita1, Carol J Homko2, Abul Kashem2, Nabeel Memon2, Alfred A Bove2.   

Abstract

BACKGROUND AND IMPORTANCE: A significant reduction in cardiovascular disease (CVD) mortality is related to aggressive management of modifiable CVD risk factors. Therefore, patients at increased risk for CVD should not only benefit from standard pharmacotherapy but also from counseling regarding lifestyle behavioral changes.
OBJECTIVE: To determine the patient factors that influence provision of cardiovascular risk reduction counseling from physicians, as well as the frequencies of counseling. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of a prospective, randomized trial among an underserved inner-city and rural population (n = 388) with a 10% or greater CVD risk (Framingham 10-year risk score). Subjects were followed for 1 year and were seen for quarterly assessments, which included evaluation of weight, blood pressure, lipid, and glucose status. At each of the 4 quarterly visits, subjects were asked if their physician had discussed or made recommendations regarding lifestyle behaviors, specifically diet, weight loss, and exercise.
RESULTS: The average patient age was 61.3 ± 10.1 years, average A1c was 6.7 ± 1.6%, average total cholesterol was 201 ± 44 mg/dL. The average body mass index (BMI) was 31.8 ± 6.4 kg/m2, and the average blood pressure was 146 ± 18/82 ±11 mm Hg. Using binary logistic regression analysis, BMI (P < .025) was the only clinical factor related to physician lifestyle counseling. All other risk factors showed no statistical relationship.
CONCLUSION: The data indicate that BMI is the major factor associated with whether or not physicians provide counseling regarding nutrition and weight loss. Physicians may be missing important opportunities to influence behavior in patients at high risk for CVD by limiting their focus to obese patients.
© The Author(s) 2015.

Entities:  

Keywords:  disease management; health promotion; obesity; patient-centeredness; prevention

Mesh:

Substances:

Year:  2015        PMID: 26574567      PMCID: PMC5932710          DOI: 10.1177/2150131915614963

Source DB:  PubMed          Journal:  J Prim Care Community Health        ISSN: 2150-1319


  27 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Physician recommendations for diet and physical activity: which patients get advised to change?

Authors:  M W Kreuter; D P Scharff; L K Brennan; S N Lukwago
Journal:  Prev Med       Date:  1997 Nov-Dec       Impact factor: 4.018

3.  Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?

Authors:  Mary Catherine Beach; Jeanne Keruly; Richard D Moore
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

4.  Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994.

Authors:  S Capewell; C E Morrison; J J McMurray
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Epidemiology of coronary heart disease: the Framingham study.

Authors:  W P Castelli
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland.

Authors:  E Vartiainen; P Puska; J Pekkanen; J Tuomilehto; P Jousilahti
Journal:  BMJ       Date:  1994-07-02

9.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

10.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

Authors:  Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.